menu
    • menu
    [{"orgOrder":0,"company":"Neuramedy","sponsor":"Bioasis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Tomaralimab","moa":"Toll-like receptor 2","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuramedy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Neuramedy \/ Bioasis","highestDevelopmentStatusID":"4","companyTruncated":"Neuramedy \/ Bioasis"},{"orgOrder":0,"company":"Neuramedy","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NM-101","moa":"Toll-like-2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Neuramedy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neuramedy \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Neuramedy \/ Quotient Sciences"},{"orgOrder":0,"company":"Neuramedy","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"NM-101","moa":"Toll-like-2 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Neuramedy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuramedy \/ Seoul National University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Neuramedy \/ Seoul National University Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals by Neuramedy

    Menu

    Neuramedy

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neuramedy

                            South Korea arrow
                            CPhI Korea
                            Not Confirmed

                            Neuramedy

                            South Korea arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NM-101

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Single Ascending Dose Study

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 18, 2025

                            Lead Product(s) : NM-101

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neuramedy

                            South Korea arrow
                            CPhI Korea
                            Not Confirmed

                            Neuramedy

                            South Korea arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NM-101

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Quotient Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single and Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of NM-101

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 30, 2023

                            Lead Product(s) : NM-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Quotient Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neuramedy

                            South Korea arrow
                            CPhI Korea
                            Not Confirmed

                            Neuramedy

                            South Korea arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tomaralimab

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Bioasis

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bioasis and Neuramedy Enter into Research Collaboration and License Agreement

                            Details : Under the terms of the agreement, Neuramedy has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            October 05, 2022

                            Lead Product(s) : Tomaralimab

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Bioasis

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth